Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience reports clinical-stage biotechnology developments in microglia-focused treatments for neurodegenerative diseases. Its updates have centered on TREM2 agonist programs, including iluzanebart, a monoclonal antibody TREM2 agonist studied in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, and VG-3927, an oral small molecule TREM2 agonist developed with an initial focus on Alzheimer’s disease.
Recurring disclosures include clinical safety, tolerability, pharmacokinetic and pharmacodynamic data, scientific conference presentations, operating results, material agreements, governance matters and capital-structure updates. The company also reported Phase 2 IGNITE results for iluzanebart in ALSP and the discontinuation of the related long-term extension study after the trial showed no beneficial biomarker or clinical efficacy effects.
Vigil Neuroscience (Nasdaq: VIGL) has updated its clinical development strategy for iluzanebart in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) following a Type C Meeting with the FDA. The company will preserve the IGNITE dataset for a final analysis at 12 months, foregoing an interim analysis. This approach aims to leverage their biomarker strategy and pursue a potential accelerated approval pathway.
The FDA has shown openness to considering accelerated approval, requesting additional data to support the proposed development plan. Vigil plans to report the final analysis from the IGNITE clinical trial in the first half of 2025, including all patients dosed with either 20 mg/kg or 40 mg/kg of iluzanebart over 12 months.
Vigil Neuroscience announced a $40 million strategic investment from Sanofi at an as-converted price of $7.44 per common share. Sanofi will acquire 537,634 Series A non-voting preferred shares, convertible into ten shares of common stock each. This investment provides Sanofi with an exclusive right of first negotiation for the license of Vigil's TREM2 agonist program, including VG-3927, currently in phase 1 trials for Alzheimer's treatment.
The funds from this investment will support Vigil's research and development, extending its cash runway into 2026. Vigil's CEO, Ivana Magovčević-Liebisch, emphasized the significance of Sanofi's investment as validation of their precision medicine approach. Sanofi's Global Head of Neurology Development, Erik Wallstroem, highlighted the importance of microglial signaling in neurodegenerative diseases and their commitment to immunoscience and neuroimmunology.
Augustine Therapeutics has secured EUR 17 million ($18.5 million) in the first closing of its Series A funding round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company, and the Charcot-Marie-Tooth Research Foundation, among others.
The funds will advance AGT100216, a selective HDAC6 inhibitor, into a Phase 1/2 clinical trial in 2025, targeting neurological diseases like Charcot-Marie-Tooth and chemotherapy-induced peripheral neuropathies. Additional funds will support pipeline development and expand the executive and R&D team.
Gerhard Koenig has been appointed as Executive Chairman of the Board, while Clara Campàs from Asabys Partners has joined the Board of Directors.
Vigil Neuroscience, a clinical-stage biotech firm focused on neurodegenerative diseases, announced its participation in two upcoming investor conferences. The company's President and CEO, Ivana Magovčević-Liebisch, and Chief Science Officer, David Gray, will join a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:30 a.m. ET. Additionally, Ivana Magovčević-Liebisch will present at the Goldman Sachs Global Healthcare Conference on June 11, 2024, at 10:40 a.m. ET. Live webcasts will be available on Vigil's website, with archived versions accessible for 90 days.
Vigil Neuroscience, Inc. (Nasdaq: VIGL) will present at the Citizens JMP Life Sciences Conference, showcasing their focus on harnessing microglia for treating neurodegenerative diseases. The management's participation in a fireside chat is scheduled for May 14th at 11:30 a.m. E.T. Interested individuals can register for the live event on the company's website. The webcast will also be accessible via the website for 90 days post-presentation.
Vigil Neuroscience, Inc. (Nasdaq: VIGL) reported its first-quarter financial results for 2024, noting progress in its clinical trials for iluzanebart and VG-3927. The company completed enrollment for Phase 2 trial of iluzanebart and is set for the next data readout in Q3 2024. VG-3927's Phase 1 trial for Alzheimer’s disease is ongoing, with interim data analysis expected in mid-2024. Vigil also appointed Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer. Financially, the company's cash position stands at $101.6 million as of March 31, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.